Tonix Pharmaceuticals Partners with Bilthoven Biologicals to Advance TNX-801 Mpox Vaccine
Tuesday, 27 August 2024, 01:59
Exciting Collaboration in Vaccine Development
Tonix Pharmaceuticals is teaming up with Bilthoven Biologicals to push forward the development of its innovative vaccine, TNX-801, aimed at combating Mpox. This initiative marks a crucial step in the evolution of vaccine technology, focusing on a potent T-cell immune response.
Key Benefits of TNX-801
- Enhanced T-cell immune response: TNX-801 aims to stimulate a robust immune reaction.
- Scalable manufacturing capabilities: This collaboration seeks to ensure the product can be produced rapidly and at scale.
- Lower dosage requirements: The vaccine uses a reduced dose compared to conventional, non-replicating vaccines, potentially improving accessibility.
The worldwide implications of this partnership could change how vaccines are developed and deployed, making them more effective against emerging infectious diseases.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.